Leuzek

Imatinib, the active ingredient in Leuzek, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is used to treat certain cancers by blocking specific cellular enzymes that drive tumor growth. GNH USA supplies Leuzek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells that depend on BCR‑ABL, c‑KIT or PDGFR signaling pathways. - Chronic myeloid leukemia: provides disease control by inhibiting the BCR‑ABL fusion protein. - Gastrointestinal stromal tumor: induces tumor regression by blocking c‑KIT and PDGFR kinases. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: offers therapeutic benefit by targeting BCR‑ABL driven proliferation.

Imatinib may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: swelling of the extremities, especially ankles. - Muscle cramps: intermittent painful contractions. - Fatigue: persistent lack of energy.

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced heart function such as dyspnea.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: check hepatic enzymes periodically. - Avoid strong CYP3A4 inhibitors: drugs like ketoconazole may increase exposure. - Use caution in patients with cardiac disease: monitor for signs of heart failure. - Pregnancy and breastfeeding: discuss potential risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture.

Imatinib can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels. - Antacids containing aluminum or magnesium: reduce absorption of the drug. - Concurrent use with other tyrosine kinase inhibitors: increases risk of toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower imatinib concentrations. - Warfarin: may require closer INR monitoring due to altered anticoagulant effect.